Apyx Medical Corp (NASDAQ: APYX) stock lost more than 24% of its trading price on the June 30 trading session. It opened trading at $6.70, dipped to $4.72, hit a high of $6.70, and closed trading at $5.03 with an intraday trading volume of 2.168 million.
In the past week, APYX stock prices declined by over 30%, and in a month, the prices slipped more than 18%. In the 52-week trading session, the stock’s highest traded price was $11.16, while the lowest was $1.31.
The market capitalization of Apyx Medical Corp is $174.027 million, and its average trading volume is 470,749. The annual price target of APYX stock is $7.67, which is just a few percent more than the current trading price.
As per data from TradingView, more than 30 Million APYX shares are free-floating, and financial backers of the company or the board of directors closely hold the remaining 4 Million shares.
Apyx Medical Corporation, the maker of Renuvion, a unique helium plasma and radiofrequency technology, stated on Friday that financial results for the second quarter of the fiscal year 2023 would be revealed after the market closes on Thursday, August 10.
Management will have a conference call on August 10 at 5:00 p.m. Eastern Time to discuss the quarter’s performance and to answer questions.
Apyx Medical Corp (NASDAQ: APYX) Earnings & Revenue
In Q1 2023, Apyx Medical Corp (NASDAQ: APYX) reported 12.06% more revenue than the estimated figures. The estimated revenue for the quarter was $10.84 million, but the reported revenue was $12.14 million.
As per analysts, the company might report $14.28 million in revenue in Q2 and $15.34 million in revenue in Q3. Earnings Per Share (EPS) of APYX surged over 25.92% compared to the predicted EPS for the quarter.
More than 80% of the company’s revenue is generated from Advanced Energy, while the remaining 15-20% is generated from Original Equipment Manufacturing. The company leads its operations predominantly in the United States along with numerous other international regions.
In the financial year 2022, Apyx Medical Corp generated $44.51 million in revenue, from which $36.08 million was reported from Advanced Energy while the remaining $7.71 million was gathered from Original Equipment Manufacturing.
From the total gathered revenue of 2022, $31.21 million was from the United States alone while the remaining $13.03 million was from other regions globally. The revenue-to-profit conversion of Apyx Medical Corp constitutes 24% of gross profit, -51% Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA), -53% Earnings before interest and taxes (EBIT), and -52% net income.
Disclaimer
The views and opinions stated by the author, or any people named in this article, are for informational ideas only and do not establish financial, investment, or other advice. Investing in or trading crypto assets comes with a risk of financial loss.
Andrew is a blockchain developer who developed his interest in cryptocurrencies while his post-graduation. He is a keen observer of details and shares his passion for writing along with being a developer. His backend knowledge about blockchain helps him give a unique perspective to his writing
Source: https://www.thecoinrepublic.com/2023/07/03/apyx-stock-plummets-24-intraday-q2-earnings-report-imminent/